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Dipeptidyl peptidase (DPP)-4 is a member of the S9b
serine protease family, which also includes DPP8 and
DPP9. DPP4 cleaves a number of regulatory factors,
including chemokines and growth factors. DPP4 inhibi-
tors have recently emerged as an effective treatment
option for type 2 diabetes. Early in vitro studies demon-
strated that DPP4 inhibitors inhibit T-cell proliferation
andcytokineproduction,leadingtotheirinvestigationin
numerous pre-clinical models of inﬂammatory diseases,
including arthritis, multiple sclerosis and inﬂammatory
bowel disease. Recent data suggest that the early DPP4-
speciﬁc inhibitors might also bind DPP8 and DPP9, thus
exerting their effects through non-speciﬁc binding. This
review highlights recent insights into the applicability of
DPP inhibitors as novel pharmacological agents for
inﬂammatory disease.
Introduction
Thedipeptidylpeptidase(DPP)-4family,alsoknownasthe
S9b family, contains four structurally homologous
enzymes, DPP4, ﬁbroblast activation protein (FAP),
DPP8 and DPP9 [1]. Enzymes within this family have a
rare substrate speciﬁcity, cleaving N-terminal dipeptides
from regulatory factors containing proline or alanine in the
penultimate position [2]. The most extensively studied and
well-characterized member of the DPP family is DPP4, a
ubiquitously expressed transmembrane glycoprotein with
known substrates that include several growth factors,
neuropeptides and chemokines (Table 1). DPP4 is also
known as the cell surface antigen CD26 and has a co-
stimulatory function in the immune response [3]. There
is increased awareness of the importance of the physio-
logical functions of DPP8 and DPP9 [1]. DPP2, which
belongs to the S28 serine protease family, lacks structural
homology to members of the S9b family; however, it is able
to bind some DPP inhibitors and has been reviewed in
detail by Maes et al. [4].
DPP4 was initially identiﬁed as a therapeutic target for
type 2 diabetes owing to its degradation of the incretin,
glucagon-like peptide (GLP)-1. Since then, several phar-
maceutical companies have released novel inhibitors, com-
monly referred to as the gliptins, that target the enzyme
activity of DPP4, thus prolonging the insulinotrophic
effects of GLP1 [5]. Altered DPP activity has been reported
in a number of disease pathologies (Table 2). In vivo and in
vitro studies have described the anti-inﬂammatory proper-
ties of non-selective DPP inhibitors, including val-pyrr, Ile-
Thia Lys[Z(NO2)]-thiazolidide and Lys[Z(NO2)]-pyrroli-
dide, suggesting pharmacological application of this novel
drug class for inﬂammatory disease. This review summar-
izes the application of DPP inhibitors to a range of disease
settings, including the clinical success of DPP4 inhibitors
for type 2 diabetes, as well as pre-clinical studies in animal
models of arthritis, multiple sclerosis (MS) and inﬂamma-
tory bowel disease (IBD). Recent insights into the selectiv-
ity of DPP inhibitors and potential off-target inhibition are
discussed.
The DPP family
DPP4
DPP4 is the archetypal member of the DPP4 family. It was
ﬁrst identiﬁed in 1966 by Hopsu-Havu and Glenner as
glycylproline naphthylamidase [6] and was puriﬁed from
rat liver and pig kidney in 1967 and 1968, respectively
[7,8]. DPP4 is a 110-kDa type-II integral membrane gly-
coprotein with ubiquitous expression. DPP4 enzyme
activity has been recorded in rats, mice and humans in
epithelial cells of the intestine, kidney, liver, lung, thymus,
lymph node, spleen, prostate and recently in adipocytes, as
well as on activated lymphocytes and monocytes [3]. There
is also a soluble form of DPP4 that is thought to result from
proteolytic cleavage of the membrane-bound form in the
circulation [1]. DPP4 is also known as the cell surface
antigen CD26 and it can associate with the lymphocyte
cell-surface molecules CD45 and adenosine deaminase to
have a co-stimulatory function in the immune response [3].
Resting B cells and natural killer (NK) cells express low
levels of CD26 on their cell surface; however, DPP4 is
signiﬁcantly upregulated in these cell types after antigenic
stimulation [9].
DPP4 is homodimeric, and possesses catalytic activity
only in its dimer form. The unique crystal structure of
DPP4 consists of two domains, an a/b-hydrolase domain
and an eight-blade b-propeller domain [3] (Figure 1). The
b-propeller encloses a large cavity that is characterized by
the catalytic triad, Ser
630, Asp
708 and His
740, which resides
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the hydrolysis of a number of regulatory factors, including
regulatory peptides, neuropeptides and chemokines, as
outlined in Table 1.
FAP, DPP8 and DPP9
DPP4, FAP, DPP8 and DPP9 are homologous enzymes
with a conserved glutamic acid motif and a Ser-Asp-His
catalytic triad [10] (Figure 1). FAP, also known as seprase,
is a 95-kDa type II integral membrane glycoprotein that is
only expressed at sites of tissue remodelling, such as
wound healing and liver cirrhosis [3]. FAP is structurally
homologous to DPP4, sharing 48% amino acid sequence
identity. In addition to its exopeptidase activity, FAP also
has endopeptidase activity, and is capable of degrading
gelatin and type I collagen [3]. Although FAP was pre-
viously considered to exist only in the membrane-bound
form, recent ﬁndings have revealed low concentrations of
circulating soluble FAP in human plasma [11].
Recently, DPP8 and DPP9 have been the focus of atten-
tion because of their immunoregulatory and therapeutic
potential. DPP8 and DPP9 have structural homology to
DPP4 and both possess the unique ability to cleave the
prolyl bond [2,12]. Both DPP8 and DPP9 share signiﬁcant
amino acid identity to DPP4. In contrast toDPP4 and FAP,
these enzymes lack a transmembrane domain and are
conﬁned to the cytoplasm [2,12]. Homology modeling of
DPP8 and DPP9 has led to a greater understanding of the
potential and catalytic mechanism of these enzymes
[13,14]. Recently, many laboratories have developed
inhibitors that distinguish between DPP4 and DPP8/9 to
further elucidate the function of this interesting family of
enzymes [15,16]. Unfortunately, DPP8/9 inhibitors bind
DPP8 and DPP9 with equal efﬁciency; thus, the aim of
current research in our laboratory is to express and purify
recombinant DPP8 and DPP9 to determine their crystal
structures. This will aid the development of inhibitors that
can discriminate between the two closely related enzymes.
Although the physiological functions of DPP8 and DPP9
remain to be determined, in vitro assays have shown that
they cleave some DPP4 substrates, including GLP1, GLP2,
neuropeptide Y (NPY), and peptide YY [17]. DP8 also
cleaves the chemotactic factors stromal cell-derived factor
(SDF)-1a and -1b, inﬂammatoryprotein-10 and interferon-
inducible T-cell chemoattractant [18]. However, these are
unlikely in vivo substrates because of the intracellular
localization of DPP8 and DPP9. Investigations to identify
in vivo substrates for these enzymes are ongoing. Cells
overexpressing DPP8 and DPP9 exhibit increased spon-
taneous apoptosis, impaired cell migration, impaired cell
adhesion and impaired wound healing, implicating a role
at sitesoftissue damageand remodeling for these enzymes
Table 1. Known DPP4 substrates and biological signiﬁcance after N-terminal cleavage
Substrate Signiﬁcance N-Terminus Reference
Regulatory peptides
Gastric inhibitory peptide (GIP) Inactivation Tyr-Ala-Asp- [63]
Gastrin-releasing peptide (GRP) Inactivation Val-Pro-Leu- [63]
GLP1 Inactivation His-Ala-Glu- [62]
GLP2 Inactivation His-Ala-Asp- [64]
Growth-hormone-releasing factor (GHRF) Inactivation Tyr-Ala-Glu- [65]
Pituitary adenylate-cyclase-activating polypeptide (PACAP)-(1–38) Inactivation His-Ser-Asp- [66]
Peptide YY(1–36) Altered receptor speciﬁcity Tyr-Pro-Ile- [67]
Neuropeptides
Neuropeptide-Y (NPY) Altered receptor speciﬁcity Tyr-Pro-Ser- [24]
Substance P Inactivation Arg-Pro-Lys- [68]
Chemokines
Eotaxin (CCL11) Altered receptor speciﬁcity Gly-Pro-Gly- [69]
IP10 (CXCL10) Altered receptor speciﬁcity Val-Pro-Leu- [18]
ITAC (CXCL11) Altered receptor speciﬁcity Phe-Pro Met- [18]
Macrophage-derived chemokine (MDC, CCL22) Altered receptor speciﬁcity Gly-Pro-Tyr- [70]
Monokine induced by IFN-g (Mig, CXCL9) Reduced activity Thr-Pro-Val- [71]
RANTES (CCL5) Altered receptor speciﬁcity Ser-Pro-Tyr- [72]
Stromal-cell-derived factor (SDF-1, CXCL12) Altered receptor speciﬁcity Lys-Pro-Val [18]
Table 2. Altered circulating DP activity and membrane DPP4 expression in both neurological and inﬂammatory diseases
Membrane
a Circulating Reference
Psychoneuroendocrine disease Anxiety ND # [55]
Anorexia and bulemia "# [56]
Depression ND # [57]
Inﬂammatory disease Arthritis ND # [40,42]
Asthma ND # [58]
Atopic dermatitis # ND [27]
Atherosclerosis " ND [59]
Chronic tonsillitis ND " [60]
IBD #" [29,48]
Multiple sclerosis " ND [28]
Systemic lupus erythematosus # ND [61]
aND, not determined; ", increased DP activity; #, decreased DP activity.
Review Trends in Pharmacological Sciences Vol.30 No.11
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activity in human leukocytes [3,20,21], suggesting that
these cells contain novel substrates for DPP8 and DPP9
and indicating an immunoregulatory function of the
enzymes.
DPP inhibitors and therapeutic potential: preclinical
models
The emergence of DPP4 and its involvement in many
disease conditions have led to the development of several
potentinhibitorsofDPP4activity[22].Theseinhibitorsare
often small-molecule compounds that competitively and
reversibly bind to the active site of the enzyme. However,
owing to structural similarities at the catalytic site of
members of the DPP4 family, the early DPP4-speciﬁc
inhibitors, such as val-pyrr, Ile-Thia and Ile-Pyrr-(2-
CN)*TFA, are non-speciﬁc and inhibit more than one
DPP [23], as demonstrated in a number of studies, casting
doubt over the molecular targets of these inhibitors
[23–25].
Altered levels of DPP4 expression and DPP enzyme
activity have been demonstrated in a number of human
diseases (Table 2). It has been reported that the signaling
capacity of DPP4 mediates immune function and disease
pathogenesis in these immune-driven conditions, in-
cluding anorexia [26], atopic dermatitis [27],M S[28]
and IBD [29]. Changes in circulating DPP enzyme activity,
originally attributed to DPP4, have also been reported
(Table 2); however, the substrates used to assess enzyme
activity, predominantly H-Ala-Pro and H-Gly-Pro, can also
becleavedbyDPP8andDPP9.Therefore,itispossiblethat
the changes in enzyme activity observed are due to mem-
bers of the DPP4 family other than DPP4. The possible
involvementofDPPsindrivingdiversedisease pathologies
has resulted in investigations into the effect of DPP inhibi-
tors in preclinical models of inﬂammatory disorders.
Type 2 diabetes mellitus
Early in vivo studies demonstrated that DPP4 inhibitors
can prolong the in vivo half-life of the incretin GLP1 in
different animal models of type 2 diabetes [30]. Several
DPP4 selective inhibitors have now been developed by
various pharmaceutical companies as treatment options
for type 2 diabetes (Table 3). In 2006, the DPP4 inhibitor
sitagliptin (Januvia
1) was granted FDA approval as a
monotherapy for type 2 diabetes. It has since gained
approval for therapeutic use in more than 40 countries
worldwide, including the USA, Europe and Australia. A
second DPP4 inhibitor, NVP-LAF237 (vildagliptin), has
been used in several large-scale clinical trials to success-
fully determine its efﬁcacy in the management of type 2
diabetes [31–33]. Recently, the European Medicines Agen-
cy has approved the combination treatment of vildagliptin
(underthetradenameGalvus
1)andtheanti-diabeticdrug
metformin for clinical use, although FDA approval for use
in the USA requires further clinical trials. Two recent
meta-analyses revealed that type 2 diabetes patients being
treated with vildagliptin or sitagliptin had a slightly
increased risk of developing an infection, speciﬁcally naso-
pharyngitis and urinary tract infection [34,35]. However,
no adverse events have been reported to date, conﬁrming
the safety and tolerability of DPP4 inhibitors.
Arthritis
In some of the earliest in vitro studies, DPP4 inhibitors
suppressed mitogen- and antigen-stimulated T-cell acti-
vation and proliferation, possibly by suppression of inter-
leukin (IL)-2 and interferon (IFN)-g production [36]. Later
studies revealed that DPP4 is also expressed on B cells and
NK cells [1]. The action of DPP4 inhibitors suggests that it
is the enzyme activity of DPP4 that mediates its immu-
nostimulatory effects and not its signaling function [37].
However, it has also been demonstrated that the enzyme
activity of DPP4 is not required for its co-stimulatory
activity of T cells; instead, CD26 can mediate its action
through direct interactions with the cell-surface molecule
CD45 [1]. Interestingly, Dpp4 gene knockout (Dpp4
 / )
Figure 1. Structural homology between members of the DPP family. (a) The DPP4
structure (PDB i.d. 1R9N; blue) is overlaid on our DPP8 model (pink) and depicted
as a ribbon diagram. The catalytic site lies between the b-propeller and the a/b-
hydrolase domains. The significant structural homology (35% amino acid identity
and 55% amino acid similarity) between the two enzymes, particularly at the active
site, indicates why so many so-called DPP4 selective inhibitors also bind other
members of the DPP family. The DPP8 model was created using Modeller 9 v. 2
[73] and the DPP4 (1R9N), FAP (1Z68) and DPP6 (1XFD) templates. Human protein
sequences were obtained from SwissProt and accession numbers are AAA51943
for DPP4 and AAG29766 for DPP8. Figure prepared using Pymol [54].( b) Schematic
representation of some members of the DPP family. The conserved glutamic acid
motif and catalytic triad residues essential for enzyme activity are highlighted. Not
to scale.
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602mice develop normally and have no obvious immune phe-
notype (Box 1) [38,39]. However, the absence of an inﬂam-
matory stimulant might have masked the potential
involvement of DPP4 in immune cell activation and pro-
liferation in these mice.
Altered DPP4 activity was ﬁrst noted in mice with
rheumatoid arthritis [40]. Soluble DPP4 enzyme activity
was signiﬁcantly decreased, whereas cell-surface expres-
sion of CD26 was increased, indicating a role in auto-
immune diseases. Tanaka et al. determined the in vivo
efﬁcacy of DPP inhibitors in normal and DPP4-deﬁcient
Fischer rats using a type II collagen-induced or alkyldia-
mine-induced rat model of arthritis [41]. The inhibitors
alanylpyrrolidine-boronic acid (Ala-boroPro), Lys-
[Z(NO2)]-thiazolidide and the irreversible Ala-Pro-nitro-
benzoylhydroxylamine were dissolved in saline and admi-
nistered orally or subcutaneously using prophylactic and
therapeutic dosage regimes. Treatment with any of the
three inhibitors reduced hind paw swelling, an indicator of
disease severity. When Lys-[Z(NO2)]-thiazolidide was
added to spleen and lymph node cell isolates from normal
and DPP4-deﬁcient Fischer rats, the inhibitor suppressed
in vitro antigen- and mitogen-induced lymphocyte prolifer-
ation in both rat strains. This ﬁnding suggests that Lys-
[Z(NO2)]-thiazolidide has broader speciﬁcity and could
have been targeting other members of the DPP4 family
such as DPP8 and DPP9.
Using Dpp4
 /  mice, Busso et al. [42] uncovered poten-
tial molecular targets for DPP4 in antigen- and collagen-
induced models of arthritis. They demonstrated a decrease
in plasma DPP activity during arthritis that could be
attributed solely to DPP4 [42]. Furthermore, damage
severity, as indicated by synovial thickness, knee-joint
inﬂammation and histological grading, was more severe
in Dpp4
 /  mice than in wild-type controls. SDF1 is a
proinﬂammatory chemotactic factor that binds to its re-
ceptor CXCR4 to stimulate cytokine production. SDF1
undergoes N-terminal truncation by DPP4, so that it is
no longer able to bind to its receptor. In this study, SDF1
concentrations were higher in Dpp4
 /  mice with exper-
imental arthritis. Busso et al. proposed that in DPP4
deﬁcient mice, SDF1 levels are not regulated and this
may contribute to the increase in disease severity observed
[42]. In vitro T-cell proliferation assays using concanavalin
A (conA) revealed no difference between wild-type and
Dpp4
 /  mice; however, IFN-g production was signiﬁ-
cantly higher in Dpp4
 /  compared to wild-type mice.
By contrast, Fan et al. [43] and Yan et al. [44] observed a
decrease in cell proliferation in Dpp4
 /  mouse spleen
lymphocytes (MSL) stimulated with conA or pokeweed
mitogen (PWM) compared to their wild-type counterparts.
However, IL-4 and IFN-g concentrations were greater in
MSL supernatants from Dpp4
 /  mice compared to wild-
type controls [44], supporting the ﬁndings of Busso et al.
Interestingly, Dpp4
 /  mice exhibited delayed secretion of
IFN-g and had lower IL-4 levels following stimulation with
PWM [44]. These data imply that Dpp4
 /  mice have an
altered immune response; however, more research is
required to delineate the mechanisms involved. Taken
together, results from these studies and those with DPP
inhibitors suggest that inhibition of DPP activity has
potential as an anti-inﬂammatory treatment modality
for arthritis, although the mechanisms by which DPP
inhibitors exert their actions are still unclear. The enzyme
activity of DPP4 is required in part for its immunomodu-
latory effects; however, the signaling function of DPP4 also
seems to play a signiﬁcant role. Furthermore, confor-
mational changes arising from interactions with speciﬁc
inhibitors at the active site might induce conformational
changes in the enzyme, leading to anti-inﬂammatory
effects (Figure 2) [43]. Moreover, it will be important to
determine whether targeted inhibition of DPP4, DPP8 or
DPP9, or a combination thereof, is required to gain thera-
peutic beneﬁt. Further work in this area is required to
answer these compelling questions.
Multiple sclerosis
DPP4 inhibitors have been extensively studied in blood
samples from patients with MS and in experimental aller-
gicencephalomyelitis(EAE),ananimalmodelofMSthatis
induced by inoculation with central nervous system anti-
genstoillicitanimmuneresponseandparalyticdisease.T-
cell clones from MS patients express signiﬁcantly higher
levels of DPP4 compared to resting peripheral blood T cells
[45]. Addition of the DPP4 inhibitor Lys[Z(NO2)]-thiazoli-
dide or Lys[Z(NO2)]-pyrrolidide to myelin basic protein-
stimulatedT-cellclonesinhibitedproductionofIL-4,IFN-g
and tumor necrosis factor (TNF)-a, suggesting that inhi-
bition of DP activity in vivo may suppress the inﬂamma-
tory response associated with MS.
Table 3. DPP4 inhibitors as therapies for type 2 diabetes
Company Inhibitor Trade name Current status
Merck Sitagliptin Januvia
1 Approved in more than 40 countries, including USA, Europe and Australia
Novartis Vildagliptin Galvus
1 Approved in Europe. Awaiting FDA approval following further Phase III trials
Bristol-Myers Squibb and
Astra Zeneca
Saxagliptin Onglyza
1 Awaiting FDA approval
Takeda Alogliptin Awaiting FDA approval
Box 1. Dpp4 knockout mice
Dpp4 knockout (Dpp4
 / ) mice were first described by Marguet et al.
and were used to demonstrate the essential role of DPP4 in the
inactivation of glucagon-line peptide GLP1 [38]. GLP1 is a potent
insulinotrophic hormone capable of stimulating glucose-dependent
insulin secretion. Dpp4
 /  mice exhibited a healthy phenotype, but
insulin secretion and glucose tolerance increased on presentation of
a glucose challenge. Despite the lack of DPP4 protein in these mice,
DPP enzyme activity is still detected, indicating that other members
o ft h eD P P 4f a m i l ya r ea c t i v e[20,37,38]. Dpp4
 /  mice have
inherently lower bodyweight than their wild-type counterparts, with
reduced food intake and increased energy expenditure, contributing
to a resistance to obesity and improved metabolic control [39].
Dpp
 /  mice have also been used to investigate the involvement of
DPP4 and other family members in animal models of disease,
including DSS-induced colitis, arthritis and MS.
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603A reduction in pro-inﬂammatory cytokine production is
evident in mice with EAE, together with an increase in
transforming growth factor (TGF)-b and reduced T-cell
proliferation after treatment with Lys[Z(NO2)]-thiazoli-
dide [45]. Preller et al. addressed the role of DPP4 in the
EAE TH1 immune response using Dpp4
 /  mice [46].
Similar to the results obtained by Busso et al. [42], EAE
disease severity was signiﬁcantly greater in Dpp4
 / 
compared to wild-type mice. Concentrations of IFN-g
and TNF-a were also elevated in Dpp4
 /  mice and latent
TGF-b was lower in comparison to wild-type controls,
implicating a direct role in the production of these cyto-
kines for DPP4. The authors proposed that synthetic and
natural ligand inhibitors of DPP4 could bind to the active
site of the enzyme, leading to a reduction in pro-inﬂam-
matory cytokines, an increase in TGF-b and decreased T-
cell proliferation, whereas this regulatory pathway might
not have been present in Dpp4
 /  mice [46]. However, the
authorsdidnotaddressthepotentialinvolvementofDPP8,
DPP9 and DPP2, which are all active in Dpp4
 /  mice and
might also play a role in regulating inﬂammatory
responses.
IBD
Although the effect of DPP4 inhibition in IBD has not been
studied extensively, much evidence indicates that DPP4
has a role in IBD pathogenesis. Serum from IBD patients
contains lower levels of circulating DPP4 activity [32,47–
49]. In vivo inhibition of DPP4 activity using val-pyrr in
healthyratsandmiceenhancestheintestinotrophiceffects
of GLP2 [50] and it has been proposed that the reduction in
soluble DPP4 activity in IBD patients might be a compen-
satory mechanism to preserve biologically active GLP21–33
[48]. However, Xiao et al. demonstrated that concen-
trations of biologically active GLP21–33 were signiﬁcantly
greater in patients with Crohn’s disease, but not ulcerative
colitis, compared to normal human controls. This indicated
that changes in GLP2 secretion during IBD are indepen-
dent of DPP4 activity [48]. This is supported by higher
membrane expression of DPP4 on T lymphocytes isolated
from IBD patients compared to healthy controls [29,47],
indicating that DPP4 might play a signiﬁcant role in
perpetuating the inﬂammatory response associated with
IBD.
We previously investigated the effect of DPP4 deﬁciency
in mice during experimental colitis. We hypothesized that
Dpp4
 /  mice would have higher concentrations of the
intestinotrophic growth factor GLP2 and therefore
increased protection and repair during dextran sulfate
sodium (DSS)-induced colitis [51]. Disease severity was
greater on day 14 and crypt area was reduced on day 9 of
DSS-induced colitis in Dpp4
 /  mice. Our study supported
the hypothesis advocated by Preller et al. that the absence
ofDPP4 on the cell surface might exaggerateinﬂammatory
responses [46]. However, there were no differences in
markers of intestinal growth, including cell proliferation,
cryptdepthandcolonweight,inDpp4
 / comparedtowild-
type mice, suggesting that the biological activity of GLP2
was not increased in these animals. Assessment of circu-
lating DP enzyme activity indicated that there was no
difference between wild-type and Dpp4
 /  mice,
suggesting that the residual DPP enzyme activity might
have been responsible for GLP2 cleavage and explaining
why no differences in these parameters were observed [51].
The effects of synthetic inhibitors of DPP4 in an animal
model of IBD have been reported by Bank et al. [52]. Using
the DSS colitis model, BALB/c mice were treated with
Lys[Z(NO2)]-pyrrolidide and an aminopeptidase N inhibi-
tor, either alone or in combination [52]. Signiﬁcant
decreases in disease activity and increased concentrations
Figure 2. Proposed working model of the potential anti-inflammatory mechanism of DPP inhibitors. After binding of the inhibitor to the active site of membrane-bound
DPP4, we propose a conformational change in the intracellular domain of the enzyme. Alternatively, the inhibitor could pass across the cell membrane and bind to DPP8 or
DPP9. This might then lead to initiation of an intracellular pathway, resulting in a reduction in pro-inflammatory cytokine secretion, suppressed T-lymphocyte proliferation
and increased production of the pro-inflammatory cytokine TGF-b. Figure adapted from data published by Fan et al. [43] and Preller et al. [46].
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combination treatment compared to vehicle treatment.
However, treatment with Lys[Z(NO2)]-pyrrolidide alone
also seemed to reduce disease severity. In our laboratory,
we recently demonstrated the efﬁcacy of two DPP inhibi-
tors, Ile-Thia and Ile-Pyrr-(2-CN)*TFA, in wild-type mice
with DSS-induced colitis. Both these inhibitors signiﬁ-
cantly reduced disease activity after 6 days of DSS inges-
tion [53]. Furthermore, histological indicators such as
crypt depth and area were improved in mice treated with
either Ile-Thia or Ile-Pyrr-(2-CN)*TFA. These studies pro-
vide further evidence of the anti-inﬂammatory effects of
DPP inhibitors. In recent work we used inhibitors on
DPP4-deﬁcient mice and found they offered no protective
effects (Yazbeck et al., unpublished data). This is further
evidence that the presence of DPP4 on the cell surface is
critical for the immunomodulatory effects of DPP4 inhibi-
tors and that the interaction between the inhibitor and
DPP4 is essential for a reduced inﬂammatory response.
Although the role of other members of the DPP family was
not speciﬁcally addressed in these studies, data from our
laboratory implicate DPP8 and DPP2 in experimental
colitis (Yazbeck et al., unpublished data). However, further
studies are required to better characterize the speciﬁc role
of these enzymes during the course of colitis.
DPPs and immune regulation
Lankas et al. demonstrated that the early DPP4 selective
inhibitors Lys[Z(NO2)]-thiazolidide and Lys[Z(NO2)]-pyr-
rolidide also inhibit DPP8, DPP9 and DPP2 [23]. This
ﬁnding suggests that off-target effects of the inhibitors
might have been, in part, responsible for their immuno-
suppressive actions, including suppression of T-lympho-
cyte proliferation and pro-inﬂammatory cytokine
production, as well as an increase in TGF-b production.
In a recent study, Reinhold et al. addressed the speciﬁc role
of DPP4, DPP8, DPP9 and DPP2 in mitogen-stimulated
MSL from wild-type and Dpp4
 /  mice [37]. The authors
demonstrated that Lys[Z(NO2)]-thiazolidide and
Lys[Z(NO2)]-pyrrolidide and a speciﬁc DPP8/9 inhibitor
all suppressed DNA synthesis in PWM-stimulated MSL
from wild-type and Dpp4
 /  mice [37]. The results of this
studyaretheﬁrsttoimplicateadirectroleinT-lymphocyte
regulation for these enzymes and suggest that they are a
novel target for immunosuppressive drug therapies. How-
ever, the authors acknowledge that DP8/9 may have been
compensating for the loss of DPP4 in Dpp4
 /  mice [37].
We propose a working model, hypothesizing potential
pathways for the anti-inﬂammatory effects of DP inhibi-
tors (Figure 2). Further studies using more potent and
selective inhibitors of each member of the DPP family are
required to characterize their role in immune regulation.
Summary
DPP4, DPP8 and DPP9 are expressed in immune cells and
represent novel pharmacological targets for inﬂammatory
diseases. DPP4, the principal member of this enzyme
family, has a number of regulatory functions, including
the hydrolysis of several peptide hormones and chemo-
kines and a co-stimulatory effect on T-cell activation via its
signaling function. The emergence of synthetic inhibitors
of DPP activity has provided a novel therapeutic option for
several human diseases, including type 2 diabetes, MS,
arthritis and IBD. The approval of the DPP4 selective
inhibitors Januvia
1 and Galvus
1 for therapeutic use in
patients with type 2 diabetes highlights the safety, toler-
ability and efﬁcacy of this class of drugs. With more se-
lective inhibitors for DPP8 and DPP9 being developed,
there is now an opportunity for researchers to delineate
the individual role of these enzymes in both innate and
adaptive immune responses. The pre-clinical data avail-
able indicate that non-selective DPP inhibitors possess
anti-inﬂammatory properties. However, further studies
are required to assess whether selective or non-selective
inhibition of DPPs is required to potentiate any anti-
inﬂammatory effects. In conclusion, DPP inhibitors
represent an exciting and novel drug class for the treat-
ment of inﬂammatory disease; however, it is essential to
deﬁne and optimize the molecular mechanismsof this drug
class before advocating any clinical use.
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